Sumitomo Pharma（4506）株式概要住友製薬株式会社日本、北米、アジアにおける医療用医薬品の製造・仕入・販売。 詳細4506 ファンダメンタル分析スノーフレーク・スコア評価5/6将来の成長1/6過去の実績4/6財務の健全性4/6配当金0/6報酬当社が推定した公正価値より45.9%で取引されている 収益は年間6.72%増加すると予測されています 過去1年間で収益は352.2%増加しました 同業他社や業界と比較して、良好な取引価格 リスク分析今後3年間の収益は年平均3.9%減少すると予測されている。 JP市場と比較して、過去 3 か月間の株価の変動が非常に大きい多額の負債を抱えている 財務結果に影響を与える大きな一時的項目 すべてのリスクチェックを見る4506 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Analyst Price TargetsAN36.3% undervaluedAnalystConsensusTarget•5mo agoFuture Margin Compression From Rising R&D And One Time Gains Will Weigh On Outlook1801AN49.1% undervaluedAnalystHighTarget•4mo agoRegenerative Medicine And Oncology Pipeline Will Reshape Long Term Earnings Profile400AN9.6% undervaluedAnalystLowTarget•5mo agoPipeline Risks And Margin Compression Will Drive Long-Term Earnings Declines400Top Analyst NarrativesAN36.3% undervaluedAnalystConsensusTarget•5mo agoFuture Margin Compression From Rising R&D And One Time Gains Will Weigh On Outlook1801AN49.1% undervaluedAnalystHighTarget•4mo agoRegenerative Medicine And Oncology Pipeline Will Reshape Long Term Earnings Profile400AN9.6% undervaluedAnalystLowTarget•5mo agoPipeline Risks And Margin Compression Will Drive Long-Term Earnings Declines400View all narrativesSumitomo Pharma Co., Ltd. 競合他社Santen PharmaceuticalSymbol: TSE:4536Market cap: JP¥618.7bOno PharmaceuticalSymbol: TSE:4528Market cap: JP¥1.0tEisaiSymbol: TSE:4523Market cap: JP¥1.1tKyowa KirinSymbol: TSE:4151Market cap: JP¥1.3t価格と性能株価の高値、安値、推移の概要Sumitomo Pharma過去の株価現在の株価JP¥1,374.5052週高値JP¥3,288.0052週安値JP¥877.00ベータ0.461ヶ月の変化-16.70%3ヶ月変化-25.10%1年変化29.91%3年間の変化111.59%5年間の変化-39.13%IPOからの変化-9.80%最新ニュースライブニュース • Jun 11Sumitomo Pharma Completes Enrollment for Key Phase 2 Enzomenib Leukemia StudySumitomo Pharma America has completed enrollment of the required number of patients for its pivotal Phase 2 monotherapy trial of enzomenib in relapsed or refractory acute leukemia. The company plans an interim analysis of the trial by the end of calendar 2026 and intends to promptly disclose the results. If the trial’s primary endpoint is met, Sumitomo Pharma America aims to move toward regulatory submissions seeking approval for enzomenib in the US and Japan in FY2027. This update indicates that the enzomenib program has reached a key operational milestone, with a defined timetable for interim data and potential regulatory steps already outlined. Investors may monitor how the interim analysis reads out, as efficacy and safety results, together with any regulatory feedback, could affect the perceived value and risk profile of Sumitomo Pharma’s oncology pipeline.ライブニュース • Jun 02Sumitomo Pharma Reports Promising Early Data for SMP-3124LP CHK1 Inhibitor in Solid TumorsSumitomo Pharma America reported first clinical data from its ongoing Phase 1/2 trial of SMP-3124LP, an investigational selective CHK1 inhibitor in a PEGylated liposome formulation. In the Phase 1 portion, SMP-3124LP was generally well tolerated with a manageable safety profile in patients with heavily pretreated advanced solid tumors. The trial showed a 48.2% disease control rate and five partial responses, and the data were presented at the 2026 ASCO Annual Meeting. These early results position SMP-3124LP as a meaningful clinical asset in Sumitomo Pharma’s oncology pipeline, with a combination of safety and antitumor activity that may support continued development. Investors should note that these are first-in-human data from an early-stage trial, so future results, regulatory feedback and any trial expansion will be important for assessing the potential contribution of this program to the company.Buy Or Sell Opportunity • May 22Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 39% to JP¥1,511. The fair value is estimated to be JP¥1,894, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 5.8% per annum. Earnings are forecast to decline by 4.5% per annum over the same time period.Reported Earnings • May 14Full year 2026 earnings: EPS and revenues exceed analyst expectationsFull year 2026 results: EPS: JP¥269 (up from JP¥59.49 in FY 2025). Revenue: JP¥453.3b (up 14% from FY 2025). Net income: JP¥106.9b (up 352% from FY 2025). Profit margin: 24% (up from 5.9% in FY 2025). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 7.6%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.お知らせ • May 13Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2026Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2026.お知らせ • May 09+ 2 more updatesSumitomo Pharma Co., Ltd. to Report Q1, 2027 Results on Jul 31, 2026Sumitomo Pharma Co., Ltd. announced that they will report Q1, 2027 results on Jul 31, 2026最新情報をもっと見るRecent updatesライブニュース • Jun 11Sumitomo Pharma Completes Enrollment for Key Phase 2 Enzomenib Leukemia StudySumitomo Pharma America has completed enrollment of the required number of patients for its pivotal Phase 2 monotherapy trial of enzomenib in relapsed or refractory acute leukemia. The company plans an interim analysis of the trial by the end of calendar 2026 and intends to promptly disclose the results. If the trial’s primary endpoint is met, Sumitomo Pharma America aims to move toward regulatory submissions seeking approval for enzomenib in the US and Japan in FY2027. This update indicates that the enzomenib program has reached a key operational milestone, with a defined timetable for interim data and potential regulatory steps already outlined. Investors may monitor how the interim analysis reads out, as efficacy and safety results, together with any regulatory feedback, could affect the perceived value and risk profile of Sumitomo Pharma’s oncology pipeline.ライブニュース • Jun 02Sumitomo Pharma Reports Promising Early Data for SMP-3124LP CHK1 Inhibitor in Solid TumorsSumitomo Pharma America reported first clinical data from its ongoing Phase 1/2 trial of SMP-3124LP, an investigational selective CHK1 inhibitor in a PEGylated liposome formulation. In the Phase 1 portion, SMP-3124LP was generally well tolerated with a manageable safety profile in patients with heavily pretreated advanced solid tumors. The trial showed a 48.2% disease control rate and five partial responses, and the data were presented at the 2026 ASCO Annual Meeting. These early results position SMP-3124LP as a meaningful clinical asset in Sumitomo Pharma’s oncology pipeline, with a combination of safety and antitumor activity that may support continued development. Investors should note that these are first-in-human data from an early-stage trial, so future results, regulatory feedback and any trial expansion will be important for assessing the potential contribution of this program to the company.Buy Or Sell Opportunity • May 22Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 39% to JP¥1,511. The fair value is estimated to be JP¥1,894, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 5.8% per annum. Earnings are forecast to decline by 4.5% per annum over the same time period.Reported Earnings • May 14Full year 2026 earnings: EPS and revenues exceed analyst expectationsFull year 2026 results: EPS: JP¥269 (up from JP¥59.49 in FY 2025). Revenue: JP¥453.3b (up 14% from FY 2025). Net income: JP¥106.9b (up 352% from FY 2025). Profit margin: 24% (up from 5.9% in FY 2025). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 7.6%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.お知らせ • May 13Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2026Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2026.お知らせ • May 09+ 2 more updatesSumitomo Pharma Co., Ltd. to Report Q1, 2027 Results on Jul 31, 2026Sumitomo Pharma Co., Ltd. announced that they will report Q1, 2027 results on Jul 31, 2026Valuation Update With 7 Day Price Move • May 01Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to JP¥1,739, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 15x in the Pharmaceuticals industry in Japan. Total returns to shareholders of 114% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥1,903 per share.お知らせ • Apr 22Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Sumitomo Pharma Co., Ltd. announced that they will report fiscal year 2026 results at 1:00 PM, Tokyo Standard Time on May 13, 2026Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to JP¥2,171, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 16x in the Pharmaceuticals industry in Japan. Total returns to shareholders of 168% over the past three years.お知らせ • Mar 03Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026Sumitomo Pharma Co., Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2026. For the year, the company revised revenue of JPY 449,000 million compared to previous guidance of JPY 429,000 million. Core operating profit of JPY 107,000 million compared to previous guidance of JPY 97,000 million. Operating profit of JPY 108,000 million compared to JPY 98,000 million. Net profit attributable to owners of the parent of JPY 102,000 million compared to previous guidance of JPY 92 million. Basic earnings per share of JPY 256.74 per share compared to previous guidance of JPY 231.57 per share. Reasons for the revisions: In the revised forecasts announced today, the Company has changed the full-year foreign exchange assumption (average exchange rate for the period) from JPY 145.0 to JPY 150.0 against 1 USD, as compared with the previous forecast. Revenue has been revised upward by JPY 20.0 billion to JPY 449.0 billion, reflecting higher than expected sales of products such as GEMTESA (therapeutic agent for overactive bladder) in the North America segment, as well as the positive impact of the weaker yen. Core operating profit has been revised upward by JPY 10.0 billion to JPY 107.0 billion. In addition to the increase in gross profit resulting from higher revenue, selling, general and administrative expenses and R&D expenses are now expected to be slightly lower than the previous forecast, excluding the impact of yen depreciation. Driven by the increase in core operating profit, operating profit has been revised upward by JPY 10.0 billion to JPY 108.0 billion and profit attributable to owners of the parent has been revised upward by JPY 10.0 billion to JPY 102.0 billion, compared with the previous forecast.Valuation Update With 7 Day Price Move • Feb 16Investor sentiment improves as stock rises 32%After last week's 32% share price gain to JP¥2,971, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 15x in the Pharmaceuticals industry in Japan. Total returns to shareholders of 245% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥5,308 per share.お知らせ • Feb 13Sumitomo Pharma Co., Ltd. and Racthera Inc. Announce Scheduled Review in Japan of the Allogeneic Ips Cell-Derived Dopaminergic Neural Proenitor Cells (Amchepry)Sumitomo Pharma Co., Ltd. and RACTHERA Inc. submitted, on August 5, 2025, an application of manufacturing and marketing authorization for allogeneic iPS cell-derived dopaminergic neural progenitor cells for indication of the improvement of motor functions during the off-time period of patients with advanced Parkinson's disease. Sumitomo Pharma and RACTHERA announced that the regenerative medical product AMCHEPRY has been listed as an item for deliberation on the agenda of the upcoming meeting of the Ministry of Health, Labour and Welfare's Pharmaceutical Affairs and Food Sanitation Council, Committee on Regenerative Medicine Products and Biotechnologies, scheduled to be held on February 19, 2026.分析記事 • Feb 06Investors Shouldn't Be Too Comfortable With Sumitomo Pharma's (TSE:4506) EarningsSumitomo Pharma Co., Ltd.'s ( TSE:4506 ) robust earnings report didn't manage to move the market for its stock. Our...Reported Earnings • Jan 31Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: JP¥22.19 (down from JP¥135 in 3Q 2025). Revenue: JP¥120.6b (up 7.3% from 3Q 2025). Net income: JP¥8.82b (down 84% from 3Q 2025). Profit margin: 7.3% (down from 48% in 3Q 2025). Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jan 22Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to JP¥2,216, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 16x in the Pharmaceuticals industry in Japan. Total returns to shareholders of 148% over the past three years.分析記事 • Jan 10Optimistic Investors Push Sumitomo Pharma Co., Ltd. (TSE:4506) Shares Up 26% But Growth Is LackingDespite an already strong run, Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have been powering on, with a gain of 26...Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 22%After last week's 22% share price gain to JP¥2,822, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 16x in the Pharmaceuticals industry in Japan. Total returns to shareholders of 216% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥4,897 per share.分析記事 • Jan 02Is Sumitomo Pharma (TSE:4506) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Price Target Changed • Nov 20Price target increased by 10% to JP¥1,821Up from JP¥1,650, the current price target is an average from 7 analysts. New target price is 33% below last closing price of JP¥2,702. Stock is up 342% over the past year. The company is forecast to post earnings per share of JP¥224 for next year compared to JP¥59.49 last year.分析記事 • Nov 13Investors Appear Satisfied With Sumitomo Pharma Co., Ltd.'s (TSE:4506) Prospects As Shares Rocket 38%Despite an already strong run, Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have been powering on, with a gain of 38...Major Estimate Revision • Nov 07Consensus EPS estimates increase by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from JP¥418.2b to JP¥424.7b. EPS estimate increased from JP¥167 to JP¥191 per share. Net income forecast to shrink 57% next year vs 9.2% growth forecast for Pharmaceuticals industry in Japan . Consensus price target up from JP¥1,599 to JP¥1,650. Share price rose 27% to JP¥2,133 over the past week.Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 27%After last week's 27% share price gain to JP¥2,133, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 15x in the Pharmaceuticals industry in Japan. Total returns to shareholders of 109% over the past three years.お知らせ • Nov 05Sumitomo Pharma Co., Ltd. to Report Q3, 2026 Results on Jan 30, 2026Sumitomo Pharma Co., Ltd. announced that they will report Q3, 2026 results at 3:30 PM, Tokyo Standard Time on Jan 30, 2026Reported Earnings • Nov 01Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: EPS: JP¥221 (up from JP¥121 loss in 2Q 2025). Revenue: JP¥119.1b (up 32% from 2Q 2025). Net income: JP¥87.7b (up JP¥135.8b from 2Q 2025). Profit margin: 74% (up from net loss in 2Q 2025). The move to profitability was primarily driven by lower expenses. Revenue exceeded analyst estimates by 6.5%. Earnings per share (EPS) also surpassed analyst estimates significantly. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 18% per year.Valuation Update With 7 Day Price Move • Sep 05Investor sentiment improves as stock rises 19%After last week's 19% share price gain to JP¥1,811, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 15x in the Pharmaceuticals industry in Japan. Total returns to shareholders of 75% over the past three years.お知らせ • Sep 01Sumitomo Pharma Co., Ltd. to Report Q2, 2026 Results on Oct 31, 2025Sumitomo Pharma Co., Ltd. announced that they will report Q2, 2026 results on Oct 31, 2025Price Target Changed • Aug 20Price target increased by 11% to JP¥1,111Up from JP¥1,004, the current price target is an average from 7 analysts. New target price is 20% below last closing price of JP¥1,382. Stock is up 126% over the past year. The company is forecast to post earnings per share of JP¥150 for next year compared to JP¥59.49 last year.分析記事 • Aug 04Results: Sumitomo Pharma Co., Ltd. Beat Earnings Expectations And Analysts Now Have New ForecastsA week ago, Sumitomo Pharma Co., Ltd. ( TSE:4506 ) came out with a strong set of first-quarter numbers that could...Reported Earnings • Aug 01First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: EPS: JP¥28.21 (down from JP¥40.11 in 1Q 2025). Revenue: JP¥108.0b (up 19% from 1Q 2025). Net income: JP¥11.2b (down 30% from 1Q 2025). Profit margin: 10% (down from 18% in 1Q 2025). Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) also surpassed analyst estimates by 37%. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.New Risk • Aug 01New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 3.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.7x net interest cover). Share price has been highly volatile over the past 3 months (10.0% average weekly change). Earnings are forecast to decline by an average of 3.0% per year for the foreseeable future. Minor Risk Large one-off items impacting financial results.お知らせ • Jul 31Marubeni Global Pharma Co., Ltd. completed the acquisition of 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506).Marubeni Global Pharma Co., Ltd. entered into Share Transfer Agreement to acquire 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) for ¥45.0 billion on April 1, 2025. A cash consideration of ¥45 billion will be paid by Marubeni Global Pharma Co., Ltd. The transaction is subject to subject to antitrust regulations. The expected completion of the transaction is from July 1, 2025 to September 30, 2025. Marubeni Global Pharma Co., Ltd. completed the acquisition of 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on July 31, 2025.Valuation Update With 7 Day Price Move • Jul 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to JP¥1,329, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 16x in the Pharmaceuticals industry in Japan. Total returns to shareholders of 25% over the past three years.分析記事 • Jul 30Sumitomo Pharma Co., Ltd.'s (TSE:4506) Shares Climb 36% But Its Business Is Yet to Catch UpSumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have continued their recent momentum with a 36% gain in the last month...Price Target Changed • Jul 30Price target increased by 16% to JP¥923Up from JP¥798, the current price target is an average from 8 analysts. New target price is 30% below last closing price of JP¥1,322. Stock is up 216% over the past year. The company is forecast to post earnings per share of JP¥131 for next year compared to JP¥59.49 last year.分析記事 • Jul 06Does Sumitomo Pharma (TSE:4506) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Jul 02Sawai Group Holdings Co., Ltd. (TSE:4887) completed the acquisition of FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506).Sawai Group Holdings Co., Ltd. (TSE:4887) agreed to acquire FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on March 28, 2025. The expected completion of the transaction is June 30, 2025. Sawai Group Holdings Co., Ltd. (TSE:4887) completed the acquisition of FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on June 30, 2025.分析記事 • Jun 15Sumitomo Pharma Co., Ltd.'s (TSE:4506) 30% Share Price Surge Not Quite Adding UpSumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have continued their recent momentum with a 30% gain in the last month...Price Target Changed • Jun 11Price target increased by 15% to JP¥760Up from JP¥664, the current price target is an average from 8 analysts. New target price is 14% below last closing price of JP¥885. Stock is up 154% over the past year. The company is forecast to post earnings per share of JP¥118 for next year compared to JP¥59.49 last year.New Risk • Jun 06New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.6% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings are forecast to decline by an average of 1.6% per year for the foreseeable future. Minor Risk Large one-off items impacting financial results.Valuation Update With 7 Day Price Move • Jun 04Investor sentiment improves as stock rises 15%After last week's 15% share price gain to JP¥876, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 15x in the Pharmaceuticals industry in Japan. Total loss to shareholders of 19% over the past three years.Major Estimate Revision • Jun 03Consensus EPS estimates increase by 40%The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate increased from JP¥80.87 to JP¥113. Revenue forecast steady at JP¥368.3b. Net income forecast to grow 91% next year vs 1.0% growth forecast for Pharmaceuticals industry in Japan. Consensus price target up from JP¥664 to JP¥678. Share price rose 9.1% to JP¥843 over the past week.分析記事 • May 20We Believe Sumitomo Pharma's (TSE:4506) Earnings Are A Poor Guide For Its ProfitabilityStrong earnings weren't enough to please Sumitomo Pharma Co., Ltd.'s ( TSE:4506 ) shareholders over the last week. We...お知らせ • May 16Sumitomo Pharma Co., Ltd. to Report Q1, 2026 Results on Jul 31, 2025Sumitomo Pharma Co., Ltd. announced that they will report Q1, 2026 results at 3:30 PM, Tokyo Standard Time on Jul 31, 2025分析記事 • May 15Sumitomo Pharma Co., Ltd. Just Recorded A 72% EPS Beat: Here's What Analysts Are Forecasting NextA week ago, Sumitomo Pharma Co., Ltd. ( TSE:4506 ) came out with a strong set of full-year numbers that could...Reported Earnings • May 14Full year 2025 earnings: EPS and revenues exceed analyst expectationsFull year 2025 results: EPS: JP¥59.49 (up from JP¥793 loss in FY 2024). Revenue: JP¥398.8b (up 27% from FY 2024). Net income: JP¥23.6b (up JP¥338.6b from FY 2024). Profit margin: 5.9% (up from net loss in FY 2024). Revenue exceeded analyst estimates by 7.1%. Earnings per share (EPS) also surpassed analyst estimates by 72%. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.お知らせ • May 13+ 1 more updateSumitomo Pharma Co., Ltd., Annual General Meeting, Jun 26, 2025Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 26, 2025.分析記事 • Apr 09Why Investors Shouldn't Be Surprised By Sumitomo Pharma Co., Ltd.'s (TSE:4506) 26% Share Price PlungeSumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have had a horrible month, losing 26% after a relatively good period...お知らせ • Apr 03Marubeni Global Pharma Co., Ltd. entered into Share Transfer Agreement to acquire 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) for ¥45.0 billion.Marubeni Global Pharma Co., Ltd. entered into Share Transfer Agreement to acquire 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) for ¥45.0 billion on April 1, 2025. A cash consideration of ¥45 billion will be paid by Marubeni Global Pharma Co., Ltd. The transaction is subject to subject to antitrust regulations. The expected completion of the transaction is from July 1, 2025 to September 30, 2025.分析記事 • Mar 19Is Sumitomo Pharma (TSE:4506) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Mar 01Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Sumitomo Pharma Co., Ltd. announced that they will report fiscal year 2025 results on May 13, 2025Price Target Changed • Feb 18Price target increased by 8.5% to JP¥593Up from JP¥546, the current price target is an average from 8 analysts. New target price is 25% below last closing price of JP¥794. Stock is up 116% over the past year. The company is forecast to post earnings per share of JP¥7.71 next year compared to a net loss per share of JP¥793 last year.分析記事 • Feb 04Sumitomo Pharma Co., Ltd. Just Recorded A 593% EPS Beat: Here's What Analysts Are Forecasting NextSumitomo Pharma Co., Ltd. ( TSE:4506 ) just released its quarterly report and things are looking bullish. Statutory...Reported Earnings • Feb 01Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: EPS: JP¥135 (up from JP¥126 loss in 3Q 2024). Revenue: JP¥112.4b (up 37% from 3Q 2024). Net income: JP¥53.4b (up JP¥103.4b from 3Q 2024). Profit margin: 48% (up from net loss in 3Q 2024). The move to profitability was primarily driven by lower expenses. Revenue exceeded analyst estimates by 24%. Earnings per share (EPS) also surpassed analyst estimates significantly. Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.お知らせ • Feb 01Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2025Sumitomo Pharma Co., Ltd. revised consolidated earnings guidance for the year ending March 31, 2025. For the year, the company expects net sales of JPY 381,000 million, Operating profit of JPY 21,000 million, Net profit attributable to owners of parent is expected to be JPY 16,000 million or JPY 40.27 earnings per share against net sales of JPY 338,000 million, Operating profit of JPY 0, Net loss attributable to owners of parent is expected to be JPY 16,000 million or JPY 40.27 Loss per share. Reasons for the revisions: The Company has changed assumed exchange rates average exchange rates) for the full-year period from its previous forecasts of JPY 145.0 to JPY 152.0 against 1 USD and JPY 20.0 to JPY 21.0 against RMB 1. Revenue is now expected to be JPY 381.0 billion, up by JPY 43.0 billion from the previous forecast, as sales of ORGOVYX® (therapeutic agent for advanced prostate cancer) and other products remain brisk in the North America segment while sales in China are exceeding plans in he Asia segment, on top of an increase due to the updated forex assumptions. Core operating profit has been revised up by JPY 29.0 billion from the previous forecast to JPY 30.0 billion. This is a result of an increase in gross profit associated with revenue increase, and an expectation that selling, general and administrative expenses and research and development expenses will remain flat due to a decrease in expenses owing to the business structure improvement at the Company, etc., despite an increase due to the updated forex assumptions. Operating profit has been revised to JPY 21.0 billion, up by JPY 21.0 billion from the previous forecast, because of the sheer magnitude of the increase in core operating profit despite the recording of expenses for business structure improvement and otherwise by the Company. Net profit attributable to owners of the parent has been revised to JPY 16.0 billion, reversing the previously forecasted loss of JPY 16.0 billion.分析記事 • Jan 11Sentiment Still Eluding Sumitomo Pharma Co., Ltd. (TSE:4506)You may think that with a price-to-sales (or "P/S") ratio of 0.6x Sumitomo Pharma Co., Ltd. ( TSE:4506 ) is a stock...分析記事 • Nov 25Sumitomo Pharma (TSE:4506) Has Debt But No Earnings; Should You Worry?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...お知らせ • Nov 10Sumitomo Pharma Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025Sumitomo Pharma Co., Ltd. announced that they will report Q3, 2025 results at 3:30 PM, Tokyo Standard Time on Jan 31, 2025New Risk • Nov 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Reported Earnings • Nov 01Second quarter 2025 earnings: EPS misses analyst expectationsSecond quarter 2025 results: JP¥121 loss per share (further deteriorated from JP¥72.68 loss in 2Q 2024). Revenue: JP¥90.1b (up 17% from 2Q 2024). Net loss: JP¥48.2b (loss widened 67% from 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.Major Estimate Revision • Oct 12Consensus EPS estimates upgraded to JP¥25.34 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -JP¥28.58 to -JP¥25.34 per share. Revenue forecast steady at JP¥343.4b. Pharmaceuticals industry in Japan expected to see average net income growth of 3.7% next year. Consensus price target up from JP¥501 to JP¥533. Share price was steady at JP¥653 over the past week.お知らせ • Sep 23Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from FTSE All-World Index (USD)Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from FTSE All-World Index (USD)分析記事 • Sep 12Is There An Opportunity With Sumitomo Pharma Co., Ltd.'s (TSE:4506) 38% Undervaluation?Key Insights The projected fair value for Sumitomo Pharma is JP¥909 based on 2 Stage Free Cash Flow to Equity Current...分析記事 • Aug 16There's No Escaping Sumitomo Pharma Co., Ltd.'s (TSE:4506) Muted Revenues Despite A 26% Share Price RiseSumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have continued their recent momentum with a 26% gain in the last month...Major Estimate Revision • Aug 14Consensus EPS estimates upgraded to JP¥39.20 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -JP¥43.68 to -JP¥39.20 per share. Revenue forecast steady at JP¥337.4b. Pharmaceuticals industry in Japan expected to see average net income growth of 0.2% next year. Consensus price target up from JP¥331 to JP¥379. Share price rose 11% to JP¥511 over the past week.Price Target Changed • Aug 07Price target increased by 14% to JP¥365Up from JP¥321, the current price target is an average from 8 analysts. New target price is 21% below last closing price of JP¥460. Stock is down 10% over the past year. The company is forecast to post a net loss per share of JP¥43.66 next year compared to a net loss per share of JP¥793 last year.お知らせ • Aug 07Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in JapanSumitomo Pharma Co., Ltd. and POXEL SA announced topline results obtained from a post-marketing clinical study, TWINKLE (TWYMEEG in diabetic patients with renal impairment: A post-marketing long-term study) (“the Study”), in Japanese type 2 diabetic patients with renal impairment for TWYMEEG Tablets 500 mg (generic name: imeglimin hydrochloride, “the Drug”) being sold in Japan, based on the Risk Management Plan. The Study was an open-label, uncontrolled, long-term study in 60 Japanese type 2 diabetic patients with renal impairment, who had no experience of type 2 diabetes treatment other than diet and exercise therapy or insufficient glycemic management in monotherapy with a hypoglycemic agent excluding insulin formulation. The Drugwas administered at 500 mg twice-daily to patients with moderate and severe renal impairment, characterized by an estimated glomerular filtration rate (eGFR) between 15 mL/min/1.73 m2 or higher to less than 45 mL/min/1.73 m2, or at 500 mg once-daily to patients with end-stage renal disease, characterized by an eGFR less than 15 mL/min/1.73m2, in monotherapy or in combination therapy with a hypoglycemic agent excluding insulin formulation, to evaluate safety and tolerability when administered orally for 52 weeks. The Drug was observed to be safe and well tolerated in Japanese type 2 diabetic patients with renal impairment and no significant differences were found in the incidence of adverse events, their types and severities in this study from previous clinical studies. Specifically, most of the adverse events were mild or moderate in severity. The incidence of serious adverse events was 16.7% (10 of 60 subjects) and causality with the Drug could be ruled out in all cases. Incidence of adverse events leading to study treatment discontinuation was also limited (4 of 60 subjects). At present, administration of the Drug is not recommended for patients with renal impairment with eGFR less than 45 mL/min/1.73m2. Based on the results of the Study, Sumitomo Pharma is planning to conduct discussions with the regulatory authorities in Japan, on revising the package insert in fiscal 20241 for patients with renal impairment with eGFR less than 45 mL/min/1.73m2.Board Change • Aug 06Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Outside Director Koji Fujimoto was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Aug 02Sumitomo Pharma Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024Sumitomo Pharma Co., Ltd. announced that they will report Q2, 2025 results on Oct 30, 2024Reported Earnings • Aug 01First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: JP¥40.11 (up from JP¥97.83 loss in 1Q 2024). Revenue: JP¥90.7b (up 20% from 1Q 2024). Net income: JP¥15.9b (up JP¥54.8b from 1Q 2024). Profit margin: 18% (up from net loss in 1Q 2024). The move to profitability was primarily driven by lower expenses. Revenue exceeded analyst estimates by 9.7%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.Major Estimate Revision • Jul 18Consensus EPS estimates upgraded to JP¥48.57 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -JP¥65.76 to -JP¥48.57 per share. Revenue forecast steady at JP¥338.2b. Pharmaceuticals industry in Japan expected to see average net income growth of 2.1% next year. Consensus price target of JP¥331 unchanged from last update. Share price rose 3.7% to JP¥423 over the past week.分析記事 • Jun 26A Piece Of The Puzzle Missing From Sumitomo Pharma Co., Ltd.'s (TSE:4506) 28% Share Price ClimbThose holding Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares would be relieved that the share price has rebounded 28% in...Major Estimate Revision • Jun 19Consensus EPS estimates upgraded to JP¥77.85 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -JP¥103 to -JP¥77.85 per share. Revenue forecast steady at JP¥339.2b. Pharmaceuticals industry in Japan expected to see average net income decline 1.0% next year. Consensus price target up from JP¥324 to JP¥331. Share price was steady at JP¥351 over the past week.Major Estimate Revision • Jun 13Consensus EPS estimates upgraded to JP¥103 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -JP¥122 to -JP¥103 per share. Revenue forecast steady at JP¥341.8b. Pharmaceuticals industry in Japan expected to see average net income decline 0.9% next year. Consensus price target broadly unchanged at JP¥321. Share price was steady at JP¥336 over the past week.お知らせ • May 24Sumitomo Pharma Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024Sumitomo Pharma Co., Ltd. announced that they will report Q1, 2025 results at 3:30 PM, Tokyo Standard Time on Jul 31, 2024お知らせ • May 16Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024.Reported Earnings • May 15Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: JP¥793 loss per share (further deteriorated from JP¥188 loss in FY 2023). Revenue: JP¥314.6b (down 43% from FY 2023). Net loss: JP¥315.0b (loss widened 323% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 59%. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.分析記事 • May 13Is Sumitomo Pharma Co., Ltd. (TSE:4506) Trading At A 34% Discount?Key Insights Sumitomo Pharma's estimated fair value is JP¥628 based on 2 Stage Free Cash Flow to Equity Sumitomo Pharma...Price Target Changed • Apr 18Price target decreased by 18% to JP¥334Down from JP¥405, the current price target is an average from 8 analysts. New target price is 15% below last closing price of JP¥394. Stock is down 53% over the past year. The company is forecast to post a net loss per share of JP¥499 next year compared to a net loss per share of JP¥188 last year.Major Estimate Revision • Apr 18Consensus EPS estimates fall by 21%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from JP¥328.3b to JP¥316.3b. Losses expected to increase from JP¥413 per share to JP¥499. Pharmaceuticals industry in Japan expected to see average net income growth of 16% next year. Consensus price target down from JP¥405 to JP¥334. Share price fell 2.5% to JP¥394 over the past week.分析記事 • Apr 17Market Cool On Sumitomo Pharma Co., Ltd.'s (TSE:4506) RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 0.5x Sumitomo Pharma Co., Ltd. ( TSE:4506 ) is a stock...お知らせ • Mar 02Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024Sumitomo Pharma Co., Ltd. announced that they will report fiscal year 2024 results on May 14, 2024Price Target Changed • Feb 22Price target decreased by 10% to JP¥413Down from JP¥460, the current price target is an average from 8 analysts. New target price is 18% above last closing price of JP¥349. Stock is down 60% over the past year. The company is forecast to post a net loss per share of JP¥399 next year compared to a net loss per share of JP¥188 last year.Major Estimate Revision • Feb 21Consensus EPS estimates fall by 24%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -JP¥281 to -JP¥350 per share. Revenue forecast unchanged at JP¥336.3b. Pharmaceuticals industry in Japan expected to see average net income growth of 14% next year. Consensus price target down from JP¥460 to JP¥428. Share price was steady at JP¥358 over the past week.Major Estimate Revision • Feb 21Consensus EPS estimates fall by 24%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -JP¥281 to -JP¥350 per share. Revenue forecast unchanged at JP¥336.3b. Pharmaceuticals industry in Japan expected to see average net income growth of 14% next year. Consensus price target down from JP¥460 to JP¥428. Share price was steady at JP¥358 over the past week.Major Estimate Revision • Feb 21Consensus EPS estimates fall by 24%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -JP¥281 to -JP¥350 per share. Revenue forecast unchanged at JP¥336.3b. Pharmaceuticals industry in Japan expected to see average net income growth of 14% next year. Consensus price target down from JP¥460 to JP¥428. Share price was steady at JP¥358 over the past week.Price Target Changed • Feb 16Price target decreased by 7.8% to JP¥442Down from JP¥479, the current price target is an average from 8 analysts. New target price is 22% above last closing price of JP¥362. Stock is down 58% over the past year. The company is forecast to post a net loss per share of JP¥301 next year compared to a net loss per share of JP¥188 last year.Major Estimate Revision • Feb 07Consensus EPS estimates fall by 23%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from JP¥342.3b to JP¥338.7b. Losses expected to increase from JP¥228 per share to JP¥281. Pharmaceuticals industry in Japan expected to see average net income growth of 15% next year. Consensus price target down from JP¥479 to JP¥460. Share price fell 21% to JP¥345 over the past week.Reported Earnings • Feb 02Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: JP¥126 loss per share (further deteriorated from JP¥28.24 loss in 3Q 2023). Revenue: JP¥82.4b (down 42% from 3Q 2023). Net loss: JP¥50.0b (loss widened 345% from 3Q 2023). Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates significantly. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance.New Risk • Feb 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (7.7% average weekly change).お知らせ • Jan 31+ 1 more updateSumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Sumitomo Pharma Co., Ltd. provided dividend guidance for the fiscal year ending March 31, 2024. For the year, the company expects to pay dividend of JPY 0.00 against JPY 7.00 a year ago.お知らせ • Dec 15Sumitomo Pharma Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024Sumitomo Pharma Co., Ltd. announced that they will report Q3, 2024 results on Jan 31, 2024お知らせ • Nov 04European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of EndometriosisGedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.お知らせ • Nov 03Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®Gedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.株主還元4506JP PharmaceuticalsJP 市場7D-4.3%-0.5%-1.4%1Y29.9%7.2%41.1%株主還元を見る業界別リターン: 4506過去 1 年間で7.2 % の収益を上げたJP Pharmaceuticals業界を上回りました。リターン対市場: 4506は、過去 1 年間で41.1 % のリターンを上げたJP市場を下回りました。価格変動Is 4506's price volatile compared to industry and market?4506 volatility4506 Average Weekly Movement9.4%Pharmaceuticals Industry Average Movement5.6%Market Average Movement4.6%10% most volatile stocks in JP Market9.3%10% least volatile stocks in JP Market2.4%安定した株価: 4506の株価は、 JP市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 4506の weekly volatility ( 9% ) は過去 1 年間安定していますが、依然としてJPの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト18973,832Toru Kimurawww.sumitomo-pharma.com住友製薬株式会社日本、北米、アジアにおける医療用医薬品の製造、仕入、販売。パーキンソン病治療薬、2型糖尿病治療薬、進行性前立腺がん治療薬、子宮筋腫・子宮内膜症治療薬、過活動膀胱治療薬、小児先天性無形成症治療薬などを提供。また、非定型抗精神病薬、ジェネリック医薬品、抗てんかん薬、非定型抗精神病薬、カルバペネム系抗生物質も提供している。さらに、動物用医薬品、医療機器なども提供している。大塚製薬株式会社と提携・ライセンス契約を締結している。旧社名は住友大日本製薬株式会社で、2022年4月に住友製薬株式会社に社名変更した。同社は1897年に設立され、大阪に本社を置いている。住友製薬は住友化学の子会社である。もっと見るSumitomo Pharma Co., Ltd. 基礎のまとめSumitomo Pharma の収益と売上を時価総額と比較するとどうか。4506 基礎統計学時価総額JP¥616.59b収益（TTM）JP¥106.87b売上高(TTM)JP¥453.29b5.8xPER（株価収益率1.4xP/Sレシオ4506 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計4506 損益計算書（TTM）収益JP¥453.29b売上原価JP¥196.40b売上総利益JP¥256.89bその他の費用JP¥150.03b収益JP¥106.87b直近の収益報告Mar 31, 2026次回決算日Jul 31, 2026一株当たり利益（EPS）238.22グロス・マージン56.67%純利益率23.58%有利子負債／自己資本比率74.3%4506 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/12 04:21終値2026/06/12 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sumitomo Pharma Co., Ltd. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。17 アナリスト機関Atsushi SekiBarclaysKoichi MameganoBofA Global ResearchHidemaru YamaguchiCitigroup Inc14 その他のアナリストを表示
ライブニュース • Jun 11Sumitomo Pharma Completes Enrollment for Key Phase 2 Enzomenib Leukemia StudySumitomo Pharma America has completed enrollment of the required number of patients for its pivotal Phase 2 monotherapy trial of enzomenib in relapsed or refractory acute leukemia. The company plans an interim analysis of the trial by the end of calendar 2026 and intends to promptly disclose the results. If the trial’s primary endpoint is met, Sumitomo Pharma America aims to move toward regulatory submissions seeking approval for enzomenib in the US and Japan in FY2027. This update indicates that the enzomenib program has reached a key operational milestone, with a defined timetable for interim data and potential regulatory steps already outlined. Investors may monitor how the interim analysis reads out, as efficacy and safety results, together with any regulatory feedback, could affect the perceived value and risk profile of Sumitomo Pharma’s oncology pipeline.
ライブニュース • Jun 02Sumitomo Pharma Reports Promising Early Data for SMP-3124LP CHK1 Inhibitor in Solid TumorsSumitomo Pharma America reported first clinical data from its ongoing Phase 1/2 trial of SMP-3124LP, an investigational selective CHK1 inhibitor in a PEGylated liposome formulation. In the Phase 1 portion, SMP-3124LP was generally well tolerated with a manageable safety profile in patients with heavily pretreated advanced solid tumors. The trial showed a 48.2% disease control rate and five partial responses, and the data were presented at the 2026 ASCO Annual Meeting. These early results position SMP-3124LP as a meaningful clinical asset in Sumitomo Pharma’s oncology pipeline, with a combination of safety and antitumor activity that may support continued development. Investors should note that these are first-in-human data from an early-stage trial, so future results, regulatory feedback and any trial expansion will be important for assessing the potential contribution of this program to the company.
Buy Or Sell Opportunity • May 22Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 39% to JP¥1,511. The fair value is estimated to be JP¥1,894, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 5.8% per annum. Earnings are forecast to decline by 4.5% per annum over the same time period.
Reported Earnings • May 14Full year 2026 earnings: EPS and revenues exceed analyst expectationsFull year 2026 results: EPS: JP¥269 (up from JP¥59.49 in FY 2025). Revenue: JP¥453.3b (up 14% from FY 2025). Net income: JP¥106.9b (up 352% from FY 2025). Profit margin: 24% (up from 5.9% in FY 2025). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 7.6%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.
お知らせ • May 13Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2026Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2026.
お知らせ • May 09+ 2 more updatesSumitomo Pharma Co., Ltd. to Report Q1, 2027 Results on Jul 31, 2026Sumitomo Pharma Co., Ltd. announced that they will report Q1, 2027 results on Jul 31, 2026
ライブニュース • Jun 11Sumitomo Pharma Completes Enrollment for Key Phase 2 Enzomenib Leukemia StudySumitomo Pharma America has completed enrollment of the required number of patients for its pivotal Phase 2 monotherapy trial of enzomenib in relapsed or refractory acute leukemia. The company plans an interim analysis of the trial by the end of calendar 2026 and intends to promptly disclose the results. If the trial’s primary endpoint is met, Sumitomo Pharma America aims to move toward regulatory submissions seeking approval for enzomenib in the US and Japan in FY2027. This update indicates that the enzomenib program has reached a key operational milestone, with a defined timetable for interim data and potential regulatory steps already outlined. Investors may monitor how the interim analysis reads out, as efficacy and safety results, together with any regulatory feedback, could affect the perceived value and risk profile of Sumitomo Pharma’s oncology pipeline.
ライブニュース • Jun 02Sumitomo Pharma Reports Promising Early Data for SMP-3124LP CHK1 Inhibitor in Solid TumorsSumitomo Pharma America reported first clinical data from its ongoing Phase 1/2 trial of SMP-3124LP, an investigational selective CHK1 inhibitor in a PEGylated liposome formulation. In the Phase 1 portion, SMP-3124LP was generally well tolerated with a manageable safety profile in patients with heavily pretreated advanced solid tumors. The trial showed a 48.2% disease control rate and five partial responses, and the data were presented at the 2026 ASCO Annual Meeting. These early results position SMP-3124LP as a meaningful clinical asset in Sumitomo Pharma’s oncology pipeline, with a combination of safety and antitumor activity that may support continued development. Investors should note that these are first-in-human data from an early-stage trial, so future results, regulatory feedback and any trial expansion will be important for assessing the potential contribution of this program to the company.
Buy Or Sell Opportunity • May 22Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 39% to JP¥1,511. The fair value is estimated to be JP¥1,894, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 5.8% per annum. Earnings are forecast to decline by 4.5% per annum over the same time period.
Reported Earnings • May 14Full year 2026 earnings: EPS and revenues exceed analyst expectationsFull year 2026 results: EPS: JP¥269 (up from JP¥59.49 in FY 2025). Revenue: JP¥453.3b (up 14% from FY 2025). Net income: JP¥106.9b (up 352% from FY 2025). Profit margin: 24% (up from 5.9% in FY 2025). Revenue exceeded analyst estimates by 2.8%. Earnings per share (EPS) also surpassed analyst estimates by 7.6%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.
お知らせ • May 13Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2026Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2026.
お知らせ • May 09+ 2 more updatesSumitomo Pharma Co., Ltd. to Report Q1, 2027 Results on Jul 31, 2026Sumitomo Pharma Co., Ltd. announced that they will report Q1, 2027 results on Jul 31, 2026
Valuation Update With 7 Day Price Move • May 01Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to JP¥1,739, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 15x in the Pharmaceuticals industry in Japan. Total returns to shareholders of 114% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥1,903 per share.
お知らせ • Apr 22Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Sumitomo Pharma Co., Ltd. announced that they will report fiscal year 2026 results at 1:00 PM, Tokyo Standard Time on May 13, 2026
Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 17%After last week's 17% share price gain to JP¥2,171, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 16x in the Pharmaceuticals industry in Japan. Total returns to shareholders of 168% over the past three years.
お知らせ • Mar 03Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026Sumitomo Pharma Co., Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2026. For the year, the company revised revenue of JPY 449,000 million compared to previous guidance of JPY 429,000 million. Core operating profit of JPY 107,000 million compared to previous guidance of JPY 97,000 million. Operating profit of JPY 108,000 million compared to JPY 98,000 million. Net profit attributable to owners of the parent of JPY 102,000 million compared to previous guidance of JPY 92 million. Basic earnings per share of JPY 256.74 per share compared to previous guidance of JPY 231.57 per share. Reasons for the revisions: In the revised forecasts announced today, the Company has changed the full-year foreign exchange assumption (average exchange rate for the period) from JPY 145.0 to JPY 150.0 against 1 USD, as compared with the previous forecast. Revenue has been revised upward by JPY 20.0 billion to JPY 449.0 billion, reflecting higher than expected sales of products such as GEMTESA (therapeutic agent for overactive bladder) in the North America segment, as well as the positive impact of the weaker yen. Core operating profit has been revised upward by JPY 10.0 billion to JPY 107.0 billion. In addition to the increase in gross profit resulting from higher revenue, selling, general and administrative expenses and R&D expenses are now expected to be slightly lower than the previous forecast, excluding the impact of yen depreciation. Driven by the increase in core operating profit, operating profit has been revised upward by JPY 10.0 billion to JPY 108.0 billion and profit attributable to owners of the parent has been revised upward by JPY 10.0 billion to JPY 102.0 billion, compared with the previous forecast.
Valuation Update With 7 Day Price Move • Feb 16Investor sentiment improves as stock rises 32%After last week's 32% share price gain to JP¥2,971, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 15x in the Pharmaceuticals industry in Japan. Total returns to shareholders of 245% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥5,308 per share.
お知らせ • Feb 13Sumitomo Pharma Co., Ltd. and Racthera Inc. Announce Scheduled Review in Japan of the Allogeneic Ips Cell-Derived Dopaminergic Neural Proenitor Cells (Amchepry)Sumitomo Pharma Co., Ltd. and RACTHERA Inc. submitted, on August 5, 2025, an application of manufacturing and marketing authorization for allogeneic iPS cell-derived dopaminergic neural progenitor cells for indication of the improvement of motor functions during the off-time period of patients with advanced Parkinson's disease. Sumitomo Pharma and RACTHERA announced that the regenerative medical product AMCHEPRY has been listed as an item for deliberation on the agenda of the upcoming meeting of the Ministry of Health, Labour and Welfare's Pharmaceutical Affairs and Food Sanitation Council, Committee on Regenerative Medicine Products and Biotechnologies, scheduled to be held on February 19, 2026.
分析記事 • Feb 06Investors Shouldn't Be Too Comfortable With Sumitomo Pharma's (TSE:4506) EarningsSumitomo Pharma Co., Ltd.'s ( TSE:4506 ) robust earnings report didn't manage to move the market for its stock. Our...
Reported Earnings • Jan 31Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: JP¥22.19 (down from JP¥135 in 3Q 2025). Revenue: JP¥120.6b (up 7.3% from 3Q 2025). Net income: JP¥8.82b (down 84% from 3Q 2025). Profit margin: 7.3% (down from 48% in 3Q 2025). Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jan 22Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to JP¥2,216, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 16x in the Pharmaceuticals industry in Japan. Total returns to shareholders of 148% over the past three years.
分析記事 • Jan 10Optimistic Investors Push Sumitomo Pharma Co., Ltd. (TSE:4506) Shares Up 26% But Growth Is LackingDespite an already strong run, Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have been powering on, with a gain of 26...
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 22%After last week's 22% share price gain to JP¥2,822, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 16x in the Pharmaceuticals industry in Japan. Total returns to shareholders of 216% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥4,897 per share.
分析記事 • Jan 02Is Sumitomo Pharma (TSE:4506) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Price Target Changed • Nov 20Price target increased by 10% to JP¥1,821Up from JP¥1,650, the current price target is an average from 7 analysts. New target price is 33% below last closing price of JP¥2,702. Stock is up 342% over the past year. The company is forecast to post earnings per share of JP¥224 for next year compared to JP¥59.49 last year.
分析記事 • Nov 13Investors Appear Satisfied With Sumitomo Pharma Co., Ltd.'s (TSE:4506) Prospects As Shares Rocket 38%Despite an already strong run, Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have been powering on, with a gain of 38...
Major Estimate Revision • Nov 07Consensus EPS estimates increase by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from JP¥418.2b to JP¥424.7b. EPS estimate increased from JP¥167 to JP¥191 per share. Net income forecast to shrink 57% next year vs 9.2% growth forecast for Pharmaceuticals industry in Japan . Consensus price target up from JP¥1,599 to JP¥1,650. Share price rose 27% to JP¥2,133 over the past week.
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 27%After last week's 27% share price gain to JP¥2,133, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 15x in the Pharmaceuticals industry in Japan. Total returns to shareholders of 109% over the past three years.
お知らせ • Nov 05Sumitomo Pharma Co., Ltd. to Report Q3, 2026 Results on Jan 30, 2026Sumitomo Pharma Co., Ltd. announced that they will report Q3, 2026 results at 3:30 PM, Tokyo Standard Time on Jan 30, 2026
Reported Earnings • Nov 01Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: EPS: JP¥221 (up from JP¥121 loss in 2Q 2025). Revenue: JP¥119.1b (up 32% from 2Q 2025). Net income: JP¥87.7b (up JP¥135.8b from 2Q 2025). Profit margin: 74% (up from net loss in 2Q 2025). The move to profitability was primarily driven by lower expenses. Revenue exceeded analyst estimates by 6.5%. Earnings per share (EPS) also surpassed analyst estimates significantly. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 18% per year.
Valuation Update With 7 Day Price Move • Sep 05Investor sentiment improves as stock rises 19%After last week's 19% share price gain to JP¥1,811, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 15x in the Pharmaceuticals industry in Japan. Total returns to shareholders of 75% over the past three years.
お知らせ • Sep 01Sumitomo Pharma Co., Ltd. to Report Q2, 2026 Results on Oct 31, 2025Sumitomo Pharma Co., Ltd. announced that they will report Q2, 2026 results on Oct 31, 2025
Price Target Changed • Aug 20Price target increased by 11% to JP¥1,111Up from JP¥1,004, the current price target is an average from 7 analysts. New target price is 20% below last closing price of JP¥1,382. Stock is up 126% over the past year. The company is forecast to post earnings per share of JP¥150 for next year compared to JP¥59.49 last year.
分析記事 • Aug 04Results: Sumitomo Pharma Co., Ltd. Beat Earnings Expectations And Analysts Now Have New ForecastsA week ago, Sumitomo Pharma Co., Ltd. ( TSE:4506 ) came out with a strong set of first-quarter numbers that could...
Reported Earnings • Aug 01First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: EPS: JP¥28.21 (down from JP¥40.11 in 1Q 2025). Revenue: JP¥108.0b (up 19% from 1Q 2025). Net income: JP¥11.2b (down 30% from 1Q 2025). Profit margin: 10% (down from 18% in 1Q 2025). Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) also surpassed analyst estimates by 37%. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
New Risk • Aug 01New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 3.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.7x net interest cover). Share price has been highly volatile over the past 3 months (10.0% average weekly change). Earnings are forecast to decline by an average of 3.0% per year for the foreseeable future. Minor Risk Large one-off items impacting financial results.
お知らせ • Jul 31Marubeni Global Pharma Co., Ltd. completed the acquisition of 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506).Marubeni Global Pharma Co., Ltd. entered into Share Transfer Agreement to acquire 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) for ¥45.0 billion on April 1, 2025. A cash consideration of ¥45 billion will be paid by Marubeni Global Pharma Co., Ltd. The transaction is subject to subject to antitrust regulations. The expected completion of the transaction is from July 1, 2025 to September 30, 2025. Marubeni Global Pharma Co., Ltd. completed the acquisition of 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on July 31, 2025.
Valuation Update With 7 Day Price Move • Jul 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to JP¥1,329, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 16x in the Pharmaceuticals industry in Japan. Total returns to shareholders of 25% over the past three years.
分析記事 • Jul 30Sumitomo Pharma Co., Ltd.'s (TSE:4506) Shares Climb 36% But Its Business Is Yet to Catch UpSumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have continued their recent momentum with a 36% gain in the last month...
Price Target Changed • Jul 30Price target increased by 16% to JP¥923Up from JP¥798, the current price target is an average from 8 analysts. New target price is 30% below last closing price of JP¥1,322. Stock is up 216% over the past year. The company is forecast to post earnings per share of JP¥131 for next year compared to JP¥59.49 last year.
分析記事 • Jul 06Does Sumitomo Pharma (TSE:4506) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Jul 02Sawai Group Holdings Co., Ltd. (TSE:4887) completed the acquisition of FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506).Sawai Group Holdings Co., Ltd. (TSE:4887) agreed to acquire FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on March 28, 2025. The expected completion of the transaction is June 30, 2025. Sawai Group Holdings Co., Ltd. (TSE:4887) completed the acquisition of FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on June 30, 2025.
分析記事 • Jun 15Sumitomo Pharma Co., Ltd.'s (TSE:4506) 30% Share Price Surge Not Quite Adding UpSumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have continued their recent momentum with a 30% gain in the last month...
Price Target Changed • Jun 11Price target increased by 15% to JP¥760Up from JP¥664, the current price target is an average from 8 analysts. New target price is 14% below last closing price of JP¥885. Stock is up 154% over the past year. The company is forecast to post earnings per share of JP¥118 for next year compared to JP¥59.49 last year.
New Risk • Jun 06New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.6% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings are forecast to decline by an average of 1.6% per year for the foreseeable future. Minor Risk Large one-off items impacting financial results.
Valuation Update With 7 Day Price Move • Jun 04Investor sentiment improves as stock rises 15%After last week's 15% share price gain to JP¥876, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 15x in the Pharmaceuticals industry in Japan. Total loss to shareholders of 19% over the past three years.
Major Estimate Revision • Jun 03Consensus EPS estimates increase by 40%The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate increased from JP¥80.87 to JP¥113. Revenue forecast steady at JP¥368.3b. Net income forecast to grow 91% next year vs 1.0% growth forecast for Pharmaceuticals industry in Japan. Consensus price target up from JP¥664 to JP¥678. Share price rose 9.1% to JP¥843 over the past week.
分析記事 • May 20We Believe Sumitomo Pharma's (TSE:4506) Earnings Are A Poor Guide For Its ProfitabilityStrong earnings weren't enough to please Sumitomo Pharma Co., Ltd.'s ( TSE:4506 ) shareholders over the last week. We...
お知らせ • May 16Sumitomo Pharma Co., Ltd. to Report Q1, 2026 Results on Jul 31, 2025Sumitomo Pharma Co., Ltd. announced that they will report Q1, 2026 results at 3:30 PM, Tokyo Standard Time on Jul 31, 2025
分析記事 • May 15Sumitomo Pharma Co., Ltd. Just Recorded A 72% EPS Beat: Here's What Analysts Are Forecasting NextA week ago, Sumitomo Pharma Co., Ltd. ( TSE:4506 ) came out with a strong set of full-year numbers that could...
Reported Earnings • May 14Full year 2025 earnings: EPS and revenues exceed analyst expectationsFull year 2025 results: EPS: JP¥59.49 (up from JP¥793 loss in FY 2024). Revenue: JP¥398.8b (up 27% from FY 2024). Net income: JP¥23.6b (up JP¥338.6b from FY 2024). Profit margin: 5.9% (up from net loss in FY 2024). Revenue exceeded analyst estimates by 7.1%. Earnings per share (EPS) also surpassed analyst estimates by 72%. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.
お知らせ • May 13+ 1 more updateSumitomo Pharma Co., Ltd., Annual General Meeting, Jun 26, 2025Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 26, 2025.
分析記事 • Apr 09Why Investors Shouldn't Be Surprised By Sumitomo Pharma Co., Ltd.'s (TSE:4506) 26% Share Price PlungeSumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have had a horrible month, losing 26% after a relatively good period...
お知らせ • Apr 03Marubeni Global Pharma Co., Ltd. entered into Share Transfer Agreement to acquire 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) for ¥45.0 billion.Marubeni Global Pharma Co., Ltd. entered into Share Transfer Agreement to acquire 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) for ¥45.0 billion on April 1, 2025. A cash consideration of ¥45 billion will be paid by Marubeni Global Pharma Co., Ltd. The transaction is subject to subject to antitrust regulations. The expected completion of the transaction is from July 1, 2025 to September 30, 2025.
分析記事 • Mar 19Is Sumitomo Pharma (TSE:4506) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Mar 01Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Sumitomo Pharma Co., Ltd. announced that they will report fiscal year 2025 results on May 13, 2025
Price Target Changed • Feb 18Price target increased by 8.5% to JP¥593Up from JP¥546, the current price target is an average from 8 analysts. New target price is 25% below last closing price of JP¥794. Stock is up 116% over the past year. The company is forecast to post earnings per share of JP¥7.71 next year compared to a net loss per share of JP¥793 last year.
分析記事 • Feb 04Sumitomo Pharma Co., Ltd. Just Recorded A 593% EPS Beat: Here's What Analysts Are Forecasting NextSumitomo Pharma Co., Ltd. ( TSE:4506 ) just released its quarterly report and things are looking bullish. Statutory...
Reported Earnings • Feb 01Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: EPS: JP¥135 (up from JP¥126 loss in 3Q 2024). Revenue: JP¥112.4b (up 37% from 3Q 2024). Net income: JP¥53.4b (up JP¥103.4b from 3Q 2024). Profit margin: 48% (up from net loss in 3Q 2024). The move to profitability was primarily driven by lower expenses. Revenue exceeded analyst estimates by 24%. Earnings per share (EPS) also surpassed analyst estimates significantly. Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 01Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2025Sumitomo Pharma Co., Ltd. revised consolidated earnings guidance for the year ending March 31, 2025. For the year, the company expects net sales of JPY 381,000 million, Operating profit of JPY 21,000 million, Net profit attributable to owners of parent is expected to be JPY 16,000 million or JPY 40.27 earnings per share against net sales of JPY 338,000 million, Operating profit of JPY 0, Net loss attributable to owners of parent is expected to be JPY 16,000 million or JPY 40.27 Loss per share. Reasons for the revisions: The Company has changed assumed exchange rates average exchange rates) for the full-year period from its previous forecasts of JPY 145.0 to JPY 152.0 against 1 USD and JPY 20.0 to JPY 21.0 against RMB 1. Revenue is now expected to be JPY 381.0 billion, up by JPY 43.0 billion from the previous forecast, as sales of ORGOVYX® (therapeutic agent for advanced prostate cancer) and other products remain brisk in the North America segment while sales in China are exceeding plans in he Asia segment, on top of an increase due to the updated forex assumptions. Core operating profit has been revised up by JPY 29.0 billion from the previous forecast to JPY 30.0 billion. This is a result of an increase in gross profit associated with revenue increase, and an expectation that selling, general and administrative expenses and research and development expenses will remain flat due to a decrease in expenses owing to the business structure improvement at the Company, etc., despite an increase due to the updated forex assumptions. Operating profit has been revised to JPY 21.0 billion, up by JPY 21.0 billion from the previous forecast, because of the sheer magnitude of the increase in core operating profit despite the recording of expenses for business structure improvement and otherwise by the Company. Net profit attributable to owners of the parent has been revised to JPY 16.0 billion, reversing the previously forecasted loss of JPY 16.0 billion.
分析記事 • Jan 11Sentiment Still Eluding Sumitomo Pharma Co., Ltd. (TSE:4506)You may think that with a price-to-sales (or "P/S") ratio of 0.6x Sumitomo Pharma Co., Ltd. ( TSE:4506 ) is a stock...
分析記事 • Nov 25Sumitomo Pharma (TSE:4506) Has Debt But No Earnings; Should You Worry?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
お知らせ • Nov 10Sumitomo Pharma Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025Sumitomo Pharma Co., Ltd. announced that they will report Q3, 2025 results at 3:30 PM, Tokyo Standard Time on Jan 31, 2025
New Risk • Nov 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Reported Earnings • Nov 01Second quarter 2025 earnings: EPS misses analyst expectationsSecond quarter 2025 results: JP¥121 loss per share (further deteriorated from JP¥72.68 loss in 2Q 2024). Revenue: JP¥90.1b (up 17% from 2Q 2024). Net loss: JP¥48.2b (loss widened 67% from 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance.
Major Estimate Revision • Oct 12Consensus EPS estimates upgraded to JP¥25.34 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -JP¥28.58 to -JP¥25.34 per share. Revenue forecast steady at JP¥343.4b. Pharmaceuticals industry in Japan expected to see average net income growth of 3.7% next year. Consensus price target up from JP¥501 to JP¥533. Share price was steady at JP¥653 over the past week.
お知らせ • Sep 23Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from FTSE All-World Index (USD)Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from FTSE All-World Index (USD)
分析記事 • Sep 12Is There An Opportunity With Sumitomo Pharma Co., Ltd.'s (TSE:4506) 38% Undervaluation?Key Insights The projected fair value for Sumitomo Pharma is JP¥909 based on 2 Stage Free Cash Flow to Equity Current...
分析記事 • Aug 16There's No Escaping Sumitomo Pharma Co., Ltd.'s (TSE:4506) Muted Revenues Despite A 26% Share Price RiseSumitomo Pharma Co., Ltd. ( TSE:4506 ) shares have continued their recent momentum with a 26% gain in the last month...
Major Estimate Revision • Aug 14Consensus EPS estimates upgraded to JP¥39.20 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -JP¥43.68 to -JP¥39.20 per share. Revenue forecast steady at JP¥337.4b. Pharmaceuticals industry in Japan expected to see average net income growth of 0.2% next year. Consensus price target up from JP¥331 to JP¥379. Share price rose 11% to JP¥511 over the past week.
Price Target Changed • Aug 07Price target increased by 14% to JP¥365Up from JP¥321, the current price target is an average from 8 analysts. New target price is 21% below last closing price of JP¥460. Stock is down 10% over the past year. The company is forecast to post a net loss per share of JP¥43.66 next year compared to a net loss per share of JP¥793 last year.
お知らせ • Aug 07Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in JapanSumitomo Pharma Co., Ltd. and POXEL SA announced topline results obtained from a post-marketing clinical study, TWINKLE (TWYMEEG in diabetic patients with renal impairment: A post-marketing long-term study) (“the Study”), in Japanese type 2 diabetic patients with renal impairment for TWYMEEG Tablets 500 mg (generic name: imeglimin hydrochloride, “the Drug”) being sold in Japan, based on the Risk Management Plan. The Study was an open-label, uncontrolled, long-term study in 60 Japanese type 2 diabetic patients with renal impairment, who had no experience of type 2 diabetes treatment other than diet and exercise therapy or insufficient glycemic management in monotherapy with a hypoglycemic agent excluding insulin formulation. The Drugwas administered at 500 mg twice-daily to patients with moderate and severe renal impairment, characterized by an estimated glomerular filtration rate (eGFR) between 15 mL/min/1.73 m2 or higher to less than 45 mL/min/1.73 m2, or at 500 mg once-daily to patients with end-stage renal disease, characterized by an eGFR less than 15 mL/min/1.73m2, in monotherapy or in combination therapy with a hypoglycemic agent excluding insulin formulation, to evaluate safety and tolerability when administered orally for 52 weeks. The Drug was observed to be safe and well tolerated in Japanese type 2 diabetic patients with renal impairment and no significant differences were found in the incidence of adverse events, their types and severities in this study from previous clinical studies. Specifically, most of the adverse events were mild or moderate in severity. The incidence of serious adverse events was 16.7% (10 of 60 subjects) and causality with the Drug could be ruled out in all cases. Incidence of adverse events leading to study treatment discontinuation was also limited (4 of 60 subjects). At present, administration of the Drug is not recommended for patients with renal impairment with eGFR less than 45 mL/min/1.73m2. Based on the results of the Study, Sumitomo Pharma is planning to conduct discussions with the regulatory authorities in Japan, on revising the package insert in fiscal 20241 for patients with renal impairment with eGFR less than 45 mL/min/1.73m2.
Board Change • Aug 06Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Outside Director Koji Fujimoto was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 02Sumitomo Pharma Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024Sumitomo Pharma Co., Ltd. announced that they will report Q2, 2025 results on Oct 30, 2024
Reported Earnings • Aug 01First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: JP¥40.11 (up from JP¥97.83 loss in 1Q 2024). Revenue: JP¥90.7b (up 20% from 1Q 2024). Net income: JP¥15.9b (up JP¥54.8b from 1Q 2024). Profit margin: 18% (up from net loss in 1Q 2024). The move to profitability was primarily driven by lower expenses. Revenue exceeded analyst estimates by 9.7%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
Major Estimate Revision • Jul 18Consensus EPS estimates upgraded to JP¥48.57 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -JP¥65.76 to -JP¥48.57 per share. Revenue forecast steady at JP¥338.2b. Pharmaceuticals industry in Japan expected to see average net income growth of 2.1% next year. Consensus price target of JP¥331 unchanged from last update. Share price rose 3.7% to JP¥423 over the past week.
分析記事 • Jun 26A Piece Of The Puzzle Missing From Sumitomo Pharma Co., Ltd.'s (TSE:4506) 28% Share Price ClimbThose holding Sumitomo Pharma Co., Ltd. ( TSE:4506 ) shares would be relieved that the share price has rebounded 28% in...
Major Estimate Revision • Jun 19Consensus EPS estimates upgraded to JP¥77.85 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -JP¥103 to -JP¥77.85 per share. Revenue forecast steady at JP¥339.2b. Pharmaceuticals industry in Japan expected to see average net income decline 1.0% next year. Consensus price target up from JP¥324 to JP¥331. Share price was steady at JP¥351 over the past week.
Major Estimate Revision • Jun 13Consensus EPS estimates upgraded to JP¥103 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -JP¥122 to -JP¥103 per share. Revenue forecast steady at JP¥341.8b. Pharmaceuticals industry in Japan expected to see average net income decline 0.9% next year. Consensus price target broadly unchanged at JP¥321. Share price was steady at JP¥336 over the past week.
お知らせ • May 24Sumitomo Pharma Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024Sumitomo Pharma Co., Ltd. announced that they will report Q1, 2025 results at 3:30 PM, Tokyo Standard Time on Jul 31, 2024
お知らせ • May 16Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024.
Reported Earnings • May 15Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: JP¥793 loss per share (further deteriorated from JP¥188 loss in FY 2023). Revenue: JP¥314.6b (down 43% from FY 2023). Net loss: JP¥315.0b (loss widened 323% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 59%. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
分析記事 • May 13Is Sumitomo Pharma Co., Ltd. (TSE:4506) Trading At A 34% Discount?Key Insights Sumitomo Pharma's estimated fair value is JP¥628 based on 2 Stage Free Cash Flow to Equity Sumitomo Pharma...
Price Target Changed • Apr 18Price target decreased by 18% to JP¥334Down from JP¥405, the current price target is an average from 8 analysts. New target price is 15% below last closing price of JP¥394. Stock is down 53% over the past year. The company is forecast to post a net loss per share of JP¥499 next year compared to a net loss per share of JP¥188 last year.
Major Estimate Revision • Apr 18Consensus EPS estimates fall by 21%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from JP¥328.3b to JP¥316.3b. Losses expected to increase from JP¥413 per share to JP¥499. Pharmaceuticals industry in Japan expected to see average net income growth of 16% next year. Consensus price target down from JP¥405 to JP¥334. Share price fell 2.5% to JP¥394 over the past week.
分析記事 • Apr 17Market Cool On Sumitomo Pharma Co., Ltd.'s (TSE:4506) RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 0.5x Sumitomo Pharma Co., Ltd. ( TSE:4506 ) is a stock...
お知らせ • Mar 02Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024Sumitomo Pharma Co., Ltd. announced that they will report fiscal year 2024 results on May 14, 2024
Price Target Changed • Feb 22Price target decreased by 10% to JP¥413Down from JP¥460, the current price target is an average from 8 analysts. New target price is 18% above last closing price of JP¥349. Stock is down 60% over the past year. The company is forecast to post a net loss per share of JP¥399 next year compared to a net loss per share of JP¥188 last year.
Major Estimate Revision • Feb 21Consensus EPS estimates fall by 24%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -JP¥281 to -JP¥350 per share. Revenue forecast unchanged at JP¥336.3b. Pharmaceuticals industry in Japan expected to see average net income growth of 14% next year. Consensus price target down from JP¥460 to JP¥428. Share price was steady at JP¥358 over the past week.
Major Estimate Revision • Feb 21Consensus EPS estimates fall by 24%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -JP¥281 to -JP¥350 per share. Revenue forecast unchanged at JP¥336.3b. Pharmaceuticals industry in Japan expected to see average net income growth of 14% next year. Consensus price target down from JP¥460 to JP¥428. Share price was steady at JP¥358 over the past week.
Major Estimate Revision • Feb 21Consensus EPS estimates fall by 24%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -JP¥281 to -JP¥350 per share. Revenue forecast unchanged at JP¥336.3b. Pharmaceuticals industry in Japan expected to see average net income growth of 14% next year. Consensus price target down from JP¥460 to JP¥428. Share price was steady at JP¥358 over the past week.
Price Target Changed • Feb 16Price target decreased by 7.8% to JP¥442Down from JP¥479, the current price target is an average from 8 analysts. New target price is 22% above last closing price of JP¥362. Stock is down 58% over the past year. The company is forecast to post a net loss per share of JP¥301 next year compared to a net loss per share of JP¥188 last year.
Major Estimate Revision • Feb 07Consensus EPS estimates fall by 23%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from JP¥342.3b to JP¥338.7b. Losses expected to increase from JP¥228 per share to JP¥281. Pharmaceuticals industry in Japan expected to see average net income growth of 15% next year. Consensus price target down from JP¥479 to JP¥460. Share price fell 21% to JP¥345 over the past week.
Reported Earnings • Feb 02Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: JP¥126 loss per share (further deteriorated from JP¥28.24 loss in 3Q 2023). Revenue: JP¥82.4b (down 42% from 3Q 2023). Net loss: JP¥50.0b (loss widened 345% from 3Q 2023). Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates significantly. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in Japan. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance.
New Risk • Feb 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (7.7% average weekly change).
お知らせ • Jan 31+ 1 more updateSumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Sumitomo Pharma Co., Ltd. provided dividend guidance for the fiscal year ending March 31, 2024. For the year, the company expects to pay dividend of JPY 0.00 against JPY 7.00 a year ago.
お知らせ • Dec 15Sumitomo Pharma Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024Sumitomo Pharma Co., Ltd. announced that they will report Q3, 2024 results on Jan 31, 2024
お知らせ • Nov 04European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of EndometriosisGedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.
お知らせ • Nov 03Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®Gedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.
